Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475

NCT02303366 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasms
Bone Neoplasms

Interventions

RADIATION: Stereotactic Ablative Body Radiosurgery (SABR)
DRUG: MK-3475

Sponsor

Peter MacCallum Cancer Centre, Australia